摘要
目的:比较拉莫三嗪合并碳酸锂和单用碳酸锂对预防双相抑郁复发的疗效以及安全性。方法:将105例接受碳酸锂治疗的临床康复期双相抑郁患者随机分为研究组(n=53)和对照组(n=53),其中研究组在碳酸锂治疗基础上合并拉莫三嗪,而对照组则在碳酸锂基础上加安慰剂,对两组进行为期1年的维持治疗,以观察维持期服药的依从性、复发率以及不良反应发生率。结果:研究组服药依从性显著高于对照组,而研究组中转躁率、复发率以及不良反应发生率均显著低于对照组(P<0.05)。结论:拉莫三嗪合并碳酸锂能降低双相抑郁患者复发的风险,且不良反应较少,患者服药依从性高。
Objective:To evaluate the efficacy and safety of lamotrigine combined with lithium carbonate versus lithium carbonate in the prevention of patients that met. Methods:All 105 patients with a CCMD - HI bipolar depression while receiving lithium treatment (0.6 - 1.2 mmol/L) were randomly assigned to one year of the treatment with lamotrigine ( titrated to 200 mg/d, n = 53 ) or placebo (n = 52). Results: Significantly more patients responded to lamotrigine combined with lithium carbonate than to lithium carbonate on- ly. Switch to mania or hypomania occurred in 4 patients (7.8%)receiving lithium carbonate only and no patients receiving lamotrigine combined with lithium carbonate. Conclusions : Lamotrigine was found effective and safe as add - on treatment to lithium in the preven- tion of bipolar depression.
出处
《中国民康医学》
2011年第5期555-557,559,共4页
Medical Journal of Chinese People’s Health
关键词
双相抑郁
预防复发
碳酸锂
拉莫三嗪
心境稳定剂
Bipolar depression
Relapse prevention
Lithium carbonate
Larnotrigine
Mood stabilizer